Authors’ Reply to the Letter by Shoar et al. on “Glycosylated Hemoglobin as a Surrogate for the Prevention of Cardiovascular Events in Cardiovascular Outcome Trials Comparing New Antidiabetic Drugs to Placebo”
https://www.hal.inserm.fr/inserm-03090462
Contributor : Christine Dupuis <>
Submitted on : Tuesday, December 29, 2020 - 4:48:58 PM Last modification on : Wednesday, December 30, 2020 - 3:32:06 AM
File
Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed
until : jamais
Pierre Ambrosi, Aurélie Daumas, Patrick Villani, Roch Giorgi. Authors’ Reply to the Letter by Shoar et al. on “Glycosylated Hemoglobin as a Surrogate for the Prevention of Cardiovascular Events in Cardiovascular Outcome Trials Comparing New Antidiabetic Drugs to Placebo”. Cardiology, Karger, 2020, 145 (6), pp.387-387. ⟨10.1159/000507361⟩. ⟨inserm-03090462⟩